TWST
NASDAQTwist Bioscience Corporation
Price$132.87-7.77 (-5.52%)
01:30 PM07:45 PM
News · 26 weeks107-12%
2026-04-192026-10-11
Mix5890d
- Insider35(60%)
- Other9(16%)
- SEC Filings8(14%)
- Analyst3(5%)
- Offering2(3%)
- Earnings1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- ANALYSTJefferies initiated coverage on Twist Bioscience with a new price targetJefferies initiated coverage of Twist Bioscience with a rating of Hold and set a new price target of $150.00
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSEC Form 4 filed by Twist Bioscience Corporation4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDEROfficer Cho Dennis sold $57,591 worth of shares (348 units at $165.49), decreasing direct ownership by 0.47% to 73,303 units (SEC Form 4) (withholding obligation)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERChief Executive Officer Leproust Emily M. sold $279,183 worth of shares (1,687 units at $165.49), decreasing direct ownership by 0.27% to 618,902 units (SEC Form 4) (for tax liability)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSVP of Human Resources Green Paula sold $48,654 worth of shares (294 units at $165.49), decreasing direct ownership by 0.25% to 116,720 units (SEC Form 4) (tax liability)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERChief Executive Officer Leproust Emily M. exercised 208,708 shares at a strike of $20.21 and sold $56,330,724 worth of shares (356,546 units at $157.99) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 620,589 units (SEC Form 4)4 - Twist Bioscience Corp (0001581280) (Issuer)
- PRTwist Bioscience Joins Lilly TuneLab to Advance Antibody Drug DiscoveryAntibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data. Participating companies m
- INSIDEROfficer Cho Dennis sold $50,521 worth of shares (412 units at $122.62), decreasing direct ownership by 0.56% to 73,651 units (SEC Form 4) (withholding tax)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERChief Executive Officer Leproust Emily M. sold $282,280 worth of shares (2,302 units at $122.62), decreasing direct ownership by 0.30% to 768,427 units (SEC Form 4) (for tax liability)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERChief Accounting Officer Werner Robert F. sold $29,185 worth of shares (238 units at $122.62), decreasing direct ownership by 0.53% to 44,399 units (SEC Form 4) to satisfy tax liability4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDERSVP of Human Resources Green Paula sold $111,220 worth of shares (907 units at $122.62), decreasing direct ownership by 0.77% to 117,014 units (SEC Form 4) to satisfy withholding tax4 - Twist Bioscience Corp (0001581280) (Issuer)
- ANALYSTBWS Financial initiated coverage on Twist Bioscience with a new price targetBWS Financial initiated coverage of Twist Bioscience with a rating of Sell and set a new price target of $45.00
- ANALYSTUBS initiated coverage on Twist Bioscience with a new price targetUBS initiated coverage of Twist Bioscience with a rating of Neutral and set a new price target of $144.00
- PRTwist Bioscience to Present at Baird 2026 Global Healthcare ConferenceTwist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the fireside chat will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience CorporationSCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)
- INSIDERChief Executive Officer Leproust Emily M. sold $6,317,760 worth of shares (41,570 units at $151.98) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 770,729 units (SEC Form 4)4 - Twist Bioscience Corp (0001581280) (Issuer)
- INSIDEROfficer Cho Dennis sold $222,227 worth of shares (1,598 units at $139.07), decreasing direct ownership by 2% to 74,063 units (SEC Form 4) to satisfy withholding tax4 - Twist Bioscience Corp (0001581280) (Issuer)
TWST FAQ
7 questionsWhat does Twist Bioscience Corporation do?
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist...Where does TWST stock trade?
Twist Bioscience Corporation (TWST) is listed on NASDAQ.What sector and industry is TWST in?
Twist Bioscience Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Twist Bioscience Corporation go public?
Twist Bioscience Corporation (TWST) completed its IPO in 2018.What are analysts saying about TWST?
Twist Bioscience Corporation has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold on 2026-10-08. Recent price targets range from $4100.00 to $4500.00.What companies are similar to TWST?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TWST side-by-side with any of them on Quantisnow.How can I track TWST on Quantisnow?
Quantisnow aggregates Twist Bioscience Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TWST to receive live email and push alerts on every new disclosure.